Treatment strategies for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: A network meta-analysis of randomised controlled trials

References

• Abramowitz JS, Taylor S, McKay D. 2009. Obsessive-compulsive disorder. Lancet. 374(9688):491–499.
   PubMed Web of Science ®Google Scholar
• Afshar H, Akuchekian S, Mahaky B, Zarean E. 2014. Topiramate augmentation in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial. J Res Med Sci. 19:976–981.
   PubMed Web of Science ®Google Scholar
• Afshar H, Roohafza H, Mohammad-Beigi H, Haghighi M, Jahangard L, Shokouh P, Sadeghi M, Hafezian H. 2012. N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 32(6):797–803.
   PubMed Web of Science ®Google Scholar
• Albert U, Marazziti D, Di Salvo G, Solia F, Rosso G, Maina G. 2018. A systematic review of evidence-based treatment strategies for obsessive- compulsive disorder resistant to first-line pharmacotherapy. Curr Med Chem. 25(41):5647–5661.
   PubMed Web of Science ®Google Scholar
• Alonso P, Cuadras D, Gabriëls L, Denys D, Goodman W, Greenberg BD, Jimenez-Ponce F, Kuhn J, Lenartz D, Mallet L, et al. 2015. Deep brain stimulation for obsessive-compulsive disorder: a meta-analysis of treatment outcome and predictors of response. PLoS One. 10(7):e0133591.
   PubMed Web of Science ®Google Scholar
• Amiaz R, Fostick L, Gershon A, Zohar J. 2008. Naltrexone augmentation in OCD: a double-blind placebo-controlled cross-over study. Eur Neuropsychopharmacol. 18(6):455–461.
   PubMed Web of Science ®Google Scholar
• Andrade C. 2015. Ondansetron augmentation of serotonin reuptake inhibitors as a treatment strategy in obsessive-compulsive disorder. J Clin Psychiatry. 76:72–75.
   PubMed Web of Science ®Google Scholar
• Andrade C. 2019. Augmentation with memantine in obsessive-compulsive disorder. J Clin Psychiatry. 80(6):19f13163.
   Web of Science ®Google Scholar
• Balachander S, Arumugham SS, Srinivas D. 2019. Ablative neurosurgery and deep brain stimulation for obsessive-compulsive disorder. Indian J Psychiatry. 61(Suppl 1):S77–S84.
   PubMedGoogle Scholar
• Bandelow B, Zohar J, Hollander E, Kasper S, Möller H-J, Zohar J, Hollander E, Kasper S, Möller H-J, Bandelow B, et al. 2008. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders – first revision. World J Biol Psychiatry. 9(4):248–312.,
   PubMed Web of Science ®Google Scholar
• Batistuzzo MC, Hoexter MQ, Taub A, Gentil AF, Cesar RCC, Joaquim MA, D'Alcante CC, McLaughlin NC, Canteras MM, Shavitt RG, et al. 2015. Visuospatial memory improvement after gamma ventral capsulotomy in treatment refractory obsessive-compulsive disorder patients. Neuropsychopharmacology. 40(8):1837–1845.
   PubMed Web of Science ®Google Scholar
• Berlin HA, Koran LM, Jenike MA, Shapira NA, Chaplin W, Pallanti S, Hollander E. 2011. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 72(5):716–721.
   PubMed Web of Science ®Google Scholar
• Bloch MH, Landeros-Weisenberger a, Kelmendi B, Coric V, Bracken MB, Leckman JF. 2006. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry. 11(7):622–632.
   PubMed Web of Science ®Google Scholar
• Brakoulias V, Stockings E. 2019. A systematic review of the use of risperidone, paliperidone and aripiprazole as augmenting agents for obsessive-compulsive disorder. Expert Opin Pharmacother. 20(1):47–53.
   PubMed Web of Science ®Google Scholar
• Brunelin J, Mondino M, Gassab L, Haesebaert F, Gaha L, Suaud-Chagny M-F, Saoud M, Mechri A, Poulet E. 2012. Examining Transcranial Direct-Current Stimulation (tDCS) as a treatment for hallucinations in schizophrenia. Am J Psychiatry. 169(7):719–724.
   PubMed Web of Science ®Google Scholar
• Bruno A, Micò U, Pandolfo G, Mallamace D, Abenavoli E, Di Nardo F, D’Arrigo C, Spina E, Zoccali RA, Muscatello MRA, et al. 2012. Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J Psychopharmacol. 26(11):1456–1462.
   PubMed Web of Science ®Google Scholar
• Burchi E, Pallanti S. 2019. Diagnostic issues in early-onset obsessive-compulsive disorder and their treatment implications. Curr Neuropharmacol. 17(8):672–680.
   PubMed Web of Science ®Google Scholar
• Carmi L, Alyagon U, Barnea-Ygael N, Zohar J, Dar R, Zangen A. 2018. Clinical and electrophysiological outcomes of deep TMS over the medial prefrontal and anterior cingulate cortices in OCD patients. Brain Stimul. 11(1):158–165.
   PubMed Web of Science ®Google Scholar
• Carmi L, Tendler A, Bystritsky A, Hollander E, Blumberger DM, Daskalakis J, Ward H, Lapidus K, Goodman W, Casuto L, et al. 2019. Efficacy and safety of deep transcranial magnetic stimulation for obsessive-compulsive disorder: a prospective multicenter randomized double-blind placebo-controlled trial. Am J Psychiatry. 176(11):931–938.
   PubMed Web of Science ®Google Scholar
• Chaimani A, Higgins JPT, Mavridis D, Spyridonos P, Salanti G. 2013. Graphical tools for network meta-analysis in STATA. PLOS One. 8(10):e76654.
   PubMed Web of Science ®Google Scholar
• Denys D, Mantione M, Figee M, van den Munckhof P, Koerselman F, Westenberg H, Bosch A, Schuurman R. 2010. Deep brain stimulation of the nucleus accumbens for treatment-refractory obsessive-compulsive disorder. Arch Gen Psychiatry. 67(10):1061–1068.
   PubMed Web of Science ®Google Scholar
• Dèttore D, Pozza A, Andersson G. 2015. Efficacy of technology-delivered cognitive behavioural therapy for OCD versus control conditions, and in comparison with therapist-administered CBT: meta-analysis of randomized controlled trials. Cogn Behav Ther. 44(3):190–211.
   PubMed Web of Science ®Google Scholar
• Dold M, Aigner M, Lanzenberger R, Kasper S. 2013. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials. Int J Neuropsychopharmacol. 16(3):557–574.
   PubMed Web of Science ®Google Scholar
• Dold M, Aigner M, Lanzenberger R, Kasper S. 2015. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: an update meta-analysis of double-blind, randomized, placebo-controlled trials. Int J Neuropsychopharmacol. 18(9):pyv047.
   PubMed Web of Science ®Google Scholar
• D'Urso G, Brunoni AR, Mazzaferro MP, Anastasia A, de Bartolomeis A, Mantovani A. 2016. Transcranial direct current stimulation for obsessive-compulsive disorder: a randomized, controlled, partial crossover trial. Depress Anxiety. 33(12):1132–1140.
   PubMed Web of Science ®Google Scholar
• Eap CB, Gründer G, Baumann P, Ansermot N, Conca A, Corruble E, Crettol S, Dahl ML, de Leon J, Greiner C, et al. 2021. Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants. World J Biol Psychiatry. 22(8):561–628.
   PubMed Web of Science ®Google Scholar
• Franklin ME, Sapyta J, Freeman JB, Khanna M, Compton S, Almirall D, Moore P, Choate-Summers M, Garcia A, Edson AL, et al. 2011. Cognitive behavior therapy augmentation of pharmacotherapy in pediatric obsessive-compulsive disorder: the Pediatric OCD Treatment Study II (POTS II) randomized controlled trial. JAMA. 306(11):1224–1232.
   PubMed Web of Science ®Google Scholar
• Geller D, Biederman J, Jones J, Park K, Schwartz S, Shapiro S, Coffey B. 1998. Is juvenile obsessive-compulsive disorder a developmental subtype of the disorder? A review of the pediatric literature. J Am Acad Child Adolesc Psychiatry. 37(4):420–427.
   PubMed Web of Science ®Google Scholar
• Goodman WK, Foote KD, Greenberg BD, Ricciuti N, Bauer R, Ward H, Shapira NA, Wu SS, Hill CL, Rasmussen SA, et al. 2010. Deep brain stimulation for intractable obsessive compulsive disorder: pilot study using a blinded, staggered-onset design. Biol Psychiatry. 67(6):535–542.
   PubMed Web of Science ®Google Scholar
• Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Charney DS. 1989. The yale-brown obsessive compulsive scale. I. Development, use, and reliability. Arch Gen Psychiatry. 46(11):1006–1011.
   PubMed Web of Science ®Google Scholar
• Grant PJ, Joseph LA, Farmer CA, Luckenbaugh DA, Lougee LC, Zarate CA, Swedo SE. 2014. 12-week, placebo-controlled trial of add-on riluzole in the treatment of childhood-onset obsessive-compulsive disorder. Neuropsychopharmacology. 39(6):1453–1459.
   PubMed Web of Science ®Google Scholar
• Haghighi M, Shayganfard M, Jahangard L, Ahmadpanah M, Bajoghli H, Pirdehghan A, Holsboer-Trachsler E, Brand S. 2015. Repetitive Transcranial Magnetic Stimulation (rTMS) improves symptoms and reduces clinical illness in patients suffering from OCD-Results from a single-blind, randomized clinical trial with sham cross-over condition. J Psychiatr Res. 68:238–244.
   PubMed Web of Science ®Google Scholar
• Hawken ER, Dilkov D, Kaludiev E, Simek S, Zhang F, Milev R. 2016. Transcranial magnetic stimulation of the supplementary motor area in the treatment of obsessive-compulsive disorder: a multi-site study. Int J Mol Sci. 17(3):420.
   PubMed Web of Science ®Google Scholar
• Hezel DM, Simpson HB. 2019. Exposure and response prevention for obsessive-compulsive disorder: a review and new directions. Indian J Psychiatry. 61(Suppl 1):S85–S92.
   PubMedGoogle Scholar
• Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, Eckermann G, Egberts K, Gerlach M, Greiner C, et al. 2018. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 51(1–02):9–62.
   PubMed Web of Science ®Google Scholar
• Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al. 2022. Cochrane Handbook for Systematic Reviews of Interventions version 6.3. Available from: www.training.cochrane.org/handbook.
   Google Scholar
• Higgins JPT, Jackson D, Barrett JK, Lu G, Ades AE, White IR. 2012. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods. 3(2):98–110.
   PubMed Web of Science ®Google Scholar
• Hirschtritt ME, Bloch MH, Mathews CA. 2017. Obsessive-compulsive disorder: advances in diagnosis and treatment. JAMA. 317(13):1358–1367.
   PubMed Web of Science ®Google Scholar
• Jackson D, Law M, Barrett JK, Turner R, Higgins JPT, Salanti G, White IR. 2016. Extending DerSimonian and Laird's methodology to perform network meta-analyses with random inconsistency effects. Stat Med. 35(6):819–839.
   PubMed Web of Science ®Google Scholar
• Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. 1996. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 17(1):1–12.
   PubMedGoogle Scholar
• Jahangard L, Haghighi M, Shyayganfard M, Ahmadpanah M, Sadeghi Bahmani D, Bajoghli H, Holsboer-Trachsler E, Brand S. 2016. Repetitive transcranial magnetic stimulation improved symptoms of obsessive-compulsive disorder, but also cognitive performance: results from a randomized clinical trial with a cross-over design and sham condition. Neuropsychobiology. 73(4):224–232.
   PubMed Web of Science ®Google Scholar
• Karthik S, Sharma LP, Narayanaswamy JC. 2020. Investigating the role of glutamate in obsessive-compulsive disorder: current perspectives. Neuropsychiatr Dis Treat. 16:1003–1013.
   PubMed Web of Science ®Google Scholar
• Khalkhali M, Aram S, Zarrabi H, Kafie M, Heidarzadeh A. 2016. Lamotrigine augmentation versus placebo in serotonin reuptake inhibitors-resistant obsessive-compulsive disorder: a randomized controlled trial. Iran J Psychiatry. 11(2):104–114.
   PubMedGoogle Scholar
• Kim D, Ryba NL, Kalabalik J, Westrich L. 2018. Critical review of the use of second-generation antipsychotics in obsessive-compulsive and related disorders. Drugs R D. 18(3):167–189.
   PubMed Web of Science ®Google Scholar
• Koran LM, Aboujaoude E, Ward H, Shapira NA, Sallee FR, Gamel N, Elliott M. 2006. Pulse-loaded intravenous clomipramine in treatment-resistant obsessive-compulsive disorder. J Clin Psychopharmacol. 26(1):79–83.
   PubMed Web of Science ®Google Scholar
• Koran LM, Hanna GL, Hollander E, Nestadt G, Simpson HB. 2007. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry. 164(7 Suppl):5–53.
   PubMed Web of Science ®Google Scholar
• Krause M, Zhu Y, Huhn M, Schneider-Thoma J, Bighelli I, Chaimani A, Leucht S. 2018. Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: a network meta-analysis. Eur Neuropsychopharmacol. 28(6):659–674.
   PubMed Web of Science ®Google Scholar
• Law C, Boisseau CL. 2019. Exposure and response prevention in the treatment of obsessive-compulsive disorder: current perspectives. Psychol Res Behav Manag. 12:1167–1174.
   PubMed Web of Science ®Google Scholar
• de Leon J, Schoretsanitis G, Kane JM, Ruan C-J. 2020. Using therapeutic drug monitoring to personalize clozapine dosing in Asians. Asia Pac Psychiatry. 12(2):e12384.
   PubMed Web of Science ®Google Scholar
• Li T, Puhan MA, Vedula SS, Singh S, Dickersin K. 2011. Network meta-analysis-highly attractive but more methodological research is needed. BMC Med. 9:79.
   PubMed Web of Science ®Google Scholar
• Lopes AC, Greenberg BD, Canteras MM, Batistuzzo MC, Hoexter MQ, Gentil AF, Pereira CAB, Joaquim MA, de Mathis ME, D'Alcante CC, et al. 2014. Gamma ventral capsulotomy for obsessive-compulsive disorder: a randomized clinical trial. JAMA Psychiatry. 71(9):1066–1076.
   PubMed Web of Science ®Google Scholar
• Lusicic A, Schruers KR, Pallanti S, Castle DJ. 2018. Transcranial magnetic stimulation in the treatment of obsessive-compulsive disorder: current perspectives. Neuropsychiatr Dis Treat. 14:1721–1736.
   PubMed Web of Science ®Google Scholar
• Martinho FP, Duarte GS, Couto F. 2020. Efficacy, effect on mood symptoms, and safety of deep brain stimulation in refractory obsessive-compulsive disorder: a systematic review and meta-analysis. J Clin Psychiatry. 81(3):19r12821.
   PubMed Web of Science ®Google Scholar
• McGuire JF, Wu MS, Piacentini J, McCracken JT, Storch EA. 2017. A meta-analysis of D-cycloserine in exposure-based treatment: moderators of treatment efficacy, response, and diagnostic remission. J Clin Psychiatry. 78(2):196–206.
   PubMed Web of Science ®Google Scholar
• McKay D, Sookman D, Neziroglu F, Wilhelm S, Stein DJ, Kyrios M, Matthews K, Veale D. 2015. Efficacy of cognitive-behavioral therapy for obsessive-compulsive disorder. Psychiatry Res. 225(3):236–246.
   PubMed Web of Science ®Google Scholar
• Menchon JM, Bobes J, Alamo C, Alonso P, García-Portilla MP, Ibáñez Á, Real E, Bousoño M, Saiz-Gonzalez MD, Saiz-Ruiz J, et al. 2019. Pharmacological treatment of obsessive compulsive disorder in adults: a clinical practice guideline based on the ADAPTE methodology. Rev Psiquiatr Salud Ment. 12(2):77–91.
   Web of Science ®Google Scholar
• Ming TS. 2016. Network meta-analyses and treatment recommendations for obsessive-compulsive disorder. Lancet Psychiatry. 3(10):920–921.
   PubMedGoogle Scholar
• Modarresi A, Chaibakhsh S, Koulaeinejad N, Koupaei SR. 2019. A systematic review and meta-analysis: memantine augmentation in moderate to severe obsessive-compulsive disorder. Psychiatry Res. 282:112602.
   PubMed Web of Science ®Google Scholar
• Modarresi A, Sayyah M, Razooghi S, Eslami K, Javadi M, Kouti L. 2018. Memantine augmentation improves symptoms in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a randomized controlled trial. Pharmacopsychiatry. 51(6):263–269.
   PubMed Web of Science ®Google Scholar
• Mohr DC, Ho J, Duffecy J, Reifler D, Sokol L, Burns MN, Jin L, Siddique J. 2012. Effect of telephone-administered vs face-to-face cognitive behavioral therapy on adherence to therapy and depression outcomes among primary care patients: a randomized trial. JAMA. 307(21):2278–2285.
   PubMed Web of Science ®Google Scholar
• Mosley PE, Windels F, Morris J, Coyne T, Marsh R, Giorni A, Mohan A, Sachdev P, O'Leary E, Boschen M, et al. 2021. A randomised, double-blind, sham-controlled trial of deep brain stimulation of the bed nucleus of the stria terminalis for treatment-resistant obsessive-compulsive disorder. Transl Psychiatry. 11(1):190.
   PubMed Web of Science ®Google Scholar
• Mowla A, Khajeian AM, Sahraian A, Chohedri AH, Kashkoli F. 2010. Topiramate augmentation in resistant OCD: a double-blind placebo-controlled clinical trial. CNS Spectr. 15(11):613–617.
   PubMed Web of Science ®Google Scholar
• Muscatello MRA, Bruno A, Pandolfo G, Micò U, Scimeca G, Romeo VM, Santoro V, Settineri S, Spina E, Zoccali RA, et al. 2011. Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J Clin Psychopharmacol. 31(2):174–179.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. 2005. Obsessive-compulsive disorder and body dysmorphic disorder: treatment. Available from: https://www.nice.org.uk/guidance/cg31/evidence.
   Google Scholar
• Olatunji BO, Davis ML, Powers MB, Smits JAJ. 2013. Cognitive-behavioral therapy for obsessive-compulsive disorder: a meta-analysis of treatment outcome and moderators. J Psychiatr Res. 47(1):33–41.
   PubMed Web of Science ®Google Scholar
• Olatunji BO, Rosenfield D, Monzani B, Krebs G, Heyman I, Turner C, Isomura K, Mataix-Cols D. 2015. Effects of homework compliance on cognitive-behavioral therapy with D-cycloserine augmentation for children with obsessive compulsive disorder. Depress Anxiety. 32(12):935–943.
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al. 2021. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 372:n71.
   PubMed Web of Science ®Google Scholar
• Pallanti S, Bernardi S, Antonini S, Singh N, Hollander E. 2014. Ondansetron augmentation in patients with obsessive-compulsive disorder who are inadequate responders to serotonin reuptake inhibitors: Improvement with treatment and worsening following discontinuation. Eur Neuropsychopharmacol. 24(3):375–380.
   PubMed Web of Science ®Google Scholar
• Pallanti S, Hollander E, Bienstock C, Koran L, Leckman J, Marazziti D, Pato M, Stein D, Zohar J. 2002. Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol. 5(2):181–191.
   PubMed Web of Science ®Google Scholar
• Rapinesi C, Kotzalidis GD, Ferracuti S, Sani G, Girardi P, Del Casale A. 2019. Brain stimulation in Obsessive-Compulsive Disorder (OCD): a systematic review. Curr Neuropharmacol. 17(8):787–807.
   PubMed Web of Science ®Google Scholar
• Reddy YJ, Sundar AS, Narayanaswamy JC, Math SB. 2017. Clinical practice guidelines for obsessive-compulsive disorder. Indian J Psychiatry. 59(5):74.
   Web of Science ®Google Scholar
• Rhodes KM, Turner RM, Higgins JPT. 2015. Predictive distributions were developed for the extent of heterogeneity in meta-analyses of continuous outcome data. J Clin Epidemiol. 68(1):52–60.
   PubMed Web of Science ®Google Scholar
• Roth Y, Tendler A, Arikan MK, Vidrine R, Kent D, Muir O, MacMillan C, Casuto L, Grammer G, Sauve W, et al. 2021. Real-world efficacy of deep TMS for obsessive-compulsive disorder: post-marketing data collected from twenty-two clinical sites. J Psychiatr Res. 137:667–672.
   PubMed Web of Science ®Google Scholar
• Sayyah M, Sayyah M, Boostani H, Ghaffari SM, Hoseini A. 2012. Effects of aripiprazole augmentation in treatment-resistant obsessive-compulsive disorder (a double blind clinical trial). Depress Anxiety. 29(10):850–854.
   PubMed Web of Science ®Google Scholar
• Scahill L, Sukhodolsky DG, Anderberg E, Dimitropoulos A, Dziura J, Aman MG, McCracken J, Tierney E, Hallett V, Katz K, et al. 2016. Sensitivity of the modified children's yale-brown obsessive compulsive scale to detect change: results from two multi-site trials. Autism. 20(2):145–152.
   PubMed Web of Science ®Google Scholar
• Selvi Y, Atli A, Aydin A, Besiroglu L, Ozdemir P, Ozdemir O. 2011. The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a single-blind, randomised study. Hum Psychopharmacol. 26(1):51–57.
   PubMed Web of Science ®Google Scholar
• Sepehrmanesh Z, Adel M, Ahmadvand A, Sehat M. 2020. Ondansetron augmentation for treatment-resistant obsessive-compulsive disorder: a randomized placebo-controlled clinical trial. Iranian Red Crescent Medical Journal. Available from: https://sites.kowsarpub.com/ircmj/articles/100918.html#abstract.
   Google Scholar
• Serata D, Kotzalidis GD, Rapinesi C, Janiri D, Di Pietro S, Callovini G, Piacentino D, Gasperoni C, Brugnoli R, Ferri VR, et al. 2015. Are 5-HT3 antagonists effective in obsessive-compulsive disorder? A systematic review of literature. Hum Psychopharmacol. 30(2):70–84.
   PubMed Web of Science ®Google Scholar
• Shapira NA, Ward HE, Mandoki M, Murphy TK, Yang MC, Blier P, Goodman WK. 2004. A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder. Biol. Psychiatry. 55(5):553–555.
   PubMed Web of Science ®Google Scholar
• Sharafkhah M, Aghakarim Alamdar M, Massoudifar A, Abdolrazaghnejad A, Ebrahimi-Monfared M, Saber R, Mohammadbeigi A. 2019. Comparing the efficacy of ondansetron and granisetron augmentation in treatment-resistant obsessive-compulsive disorder: a randomized double-blind placebo-controlled study. Int Clin Psychopharmacol. 34(5):222–233.
   PubMed Web of Science ®Google Scholar
• Shayganfard M, Jahangard L, Nazaribadie M, Haghighi M, Ahmadpanah M, Sadeghi Bahmani D, Bajoghli H, Holsboer-Trachsler E, Brand S. 2016. Repetitive transcranial magnetic stimulation improved symptoms of obsessive-compulsive disorders but not executive functions: results from a randomized clinical trial with crossover design and sham condition. Neuropsychobiology. 74(2):115–124.
   PubMed Web of Science ®Google Scholar
• Shoja Shafti S, Kaviani H. 2015. Aripiprazole versus quetiapine in treatment-resistant obsessive-compulsive disorder: a double-blind clinical trial. Ther Adv Psychopharmacol. 5(1):32–37.
   PubMed Web of Science ®Google Scholar
• Sijercic I, Whitfield KM, Cassin SE, Antony MM. 2020. A systematic review of cognitive-behavioral therapy for pharmacotherapy treatment-resistant obsessive-compulsive disorder. Journal of Obsessive-Compulsive and Related Disorders. 26:100532.
   Web of Science ®Google Scholar
• Simpson HB, Foa EB, Liebowitz MR, Huppert JD, Cahill S, Maher MJ, McLean CP, Bender J, Marcus SM, Williams MT, et al. 2013. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial. JAMA Psychiatry. 70(11):1190–1199.
   PubMed Web of Science ®Google Scholar
• Skapinakis P, Caldwell DM, Hollingworth W, Bryden P, Fineberg NA, Salkovskis P, Welton NJ, Baxter H, Kessler D, Churchill R, et al. 2016. Pharmacological and psychotherapeutic int-erventions for management of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis. Lancet Psychiatry. 3(8):730–739.
   PubMed Web of Science ®Google Scholar
• Skapinakis P, Papatheodorou T, Mavreas V. 2007. Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: a meta-analysis of the randomized controlled trials. Eur Neuropsychopharmacol. 17(2):79–93.
   PubMed Web of Science ®Google Scholar
• Storch EA, Goddard AW, Grant JE, De Nadai AS, Goodman WK, Mutch PJ, Medlock C, Odlaug B, McDougle CJ, Murphy TK, et al. 2013. Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder. J Clin Psychiatry. 74(06):e527–e532.
   PubMedGoogle Scholar
• Suhas S, Kumar V, Damodharan D, Sharma P, Rao NP, Varambally S, Venkatasubramanian G, Murthy P, Gangadhar BN. 2020. Do Indian patients with schizophrenia need half the recommended clozapine dose to achieve therapeutic serum level? An exploratory study. Schizophrenia Res. 222:195–201.
   PubMed Web of Science ®Google Scholar
• Talaei A, Hosseini FF, Aghili Z, Akhondzadeh S, Asadpour E, Mehramiz NJ, Forouzanfar F. 2020. A comparative, single-blind, randomized study on quetiapine and aripiperazole augmentation in treatment of selective serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Can J Physiol Pharmacol. 98(4):236–242.
   PubMed Web of Science ®Google Scholar
• Trevizol AP, Shiozawa P, Cook IA, Sato IA, Kaku CB, Guimarães FB, Sachdev P, Sarkhel S, Cordeiro Q. 2016. Transcranial magnetic stimulation for obsessive-compulsive disorder: an updated systematic review and meta-analysis. J Ect. 32(4):262–266.
   PubMed Web of Science ®Google Scholar
• Veale D, Miles S, Smallcombe N, Ghezai H, Goldacre B, Hodsoll J. 2014. Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis. BMC Psychiatry. 14:317.
   PubMed Web of Science ®Google Scholar
• Wheaton MG, DeSantis SM, Simpson HB. 2016. Network meta-analyses and treatment recommendations for obsessive-compulsive disorder. Lancet Psychiatry. 3(10):920.
   PubMedGoogle Scholar
• White IR, Barrett JK, Jackson D, Higgins JPT. 2012. Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. Res Synth Methods. 3(2):111–125.
   PubMed Web of Science ®Google Scholar
• White IR, Thomas J. 2016. Standardized mean differences in individually-randomized and cluster-randomized trials, with applications to meta-analysis: Clinical Trials. Available from: 10.1191/1740774505cn081oa.
   Google Scholar
• Xia J, Du Y, Han J, Liu G, Wang X. 2015. D-cycloserine augmentation in behavioral therapy for obsessive-compulsive disorder: a meta-analysis. Drug Des Devel Ther. 9:2101–2117.
   PubMed Web of Science ®Google Scholar
• Zhou D-D, Zhou X-X, Li Y, Zhang K-F, Lv Z, Chen X-R, Wan L-Y, Wang W, Wang G-M, Li D-Q, et al. 2019. Augmentation agents to serotonin reuptake inhibitors for treatment-resistant obsessive-compulsive disorder: a network meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 90:277–287.
   PubMed Web of Science ®Google Scholar
• Zhou D-D, Zhou X-X, Lv Z, Chen X-R, Wang W, Wang G-M, Liu C, Li D-Q, Kuang L. 2019. Comparative efficacy and tolerability of antipsychotics as augmentations in adults with treatment-resistant obsessive-compulsive disorder: a network meta-analysis. J Psychiatr Res. 111:51–58.
   PubMed Web of Science ®Google Scholar